Castanin

Castanin

SCHEMBL572274

COc1ccc(-c2coc3cc(O)c(OC)cc3c2=O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 1.00
KLK7 P49862 1/20 1.00
HDAC6 Q9UBN7 2/20 0.83
PPARG P37231 2/20 0.79
PTPN1 P18031 1/20 0.79
MAPT P10636 9/20 0.69
ALDH1A1 P00352 7/20 0.69
MEN1 O00255 6/20 0.69
KMT2A Q03164 6/20 0.69
CYP3A4 P08684 6/20 0.69
KDM4E B2RXH2 6/20 0.69
SMN1; SMN2 Q16637 5/20 0.69
TP53 P04637 5/20 0.69
HSD17B10 Q99714 4/20 0.69
CYP2D6 P10635 3/20 0.69
CYP2C9 P11712 3/20 0.69
CYP2C19 P33261 3/20 0.69
HPGD P15428 3/20 0.69
MAOA P21397 2/20 0.69
MAOB P27338 2/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29448332 0.95 RAB9A (0.90) RAB9AKLK7HDAC6PPARGPTPN1
Glycitein SCHEMBL6578666 0.92 RAB9A (0.85) RAB9AKLK7HDAC6PPARGPTPN1
Glycitein SCHEMBL29497281 0.91 HDAC6 (1.00) RAB9AKLK7HDAC6PPARGPTPN1
Glycitein SCHEMBL19720 0.91 HDAC6 (1.00) RAB9AKLK7HDAC6PPARGPTPN1
Glycitein SCHEMBL7733712 0.91 HDAC6 (1.00) RAB9AKLK7HDAC6PPARGPTPN1
Formonetin SCHEMBL4728656 0.91 RAB9A (0.83) RAB9AKLK7HDAC6PPARGPTPN1
SCHEMBL7030328 0.89 RAB9A (0.81) RAB9AKLK7HDAC6PPARGPTPN1
SCHEMBL30573375 0.89 RAB9A (0.81) RAB9AKLK7HDAC6PPARGPTPN1
SCHEMBL5423281 0.89 RAB9A (0.80) RAB9AKLK7HDAC6PPARGPTPN1
Odoratin SCHEMBL1248967 0.88 PTPN1 (1.00) RAB9AKLK7HDAC6PPARGPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US claimed
EP-4583856-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS Native Code Bio, LLC (US) 2025-07-16 EP claimed
WO-2024054688-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO, LLC (US) 2024-03-14 WO claimed
CN-114642695-A Big data traditional Chinese medicine composition for regulating and controlling prostate cancer 华子昂 2022-06-21 CN claimed
CN-104822424-A Oral compositions for enhancing skin tolerance following topical application of retinoid compounds INNEOV LAB 2015-08-05 CN claimed
CN-104661692-A Balloon surface coating for valvuloplasty CARDIONOVUM GMBH 2015-05-27 CN claimed
CN-104394898-A Balloon surface coating CARDIONOVUM GMBH 2015-03-04 CN claimed
CN-103702654-A Use of a combination of a carotenoid, a phytoestrogen and vitamin C for the prevention and/or treatment of pigmentation disorders INNEOV LAB 2014-04-02 CN claimed
CN-103596548-A Combination of carotenoids, phytoestrogens and vitamin C for skin moisturization INNEOV LAB 2014-02-19 CN claimed
CN-101636187-B Biodegradable vascular support HEMOTEQ AG 2013-08-28 CN claimed
CN-103025362-A Coating of endoprostheses with a coating consisting of a tight mesh of polymer fibres HEMOTEQ AG 2013-04-03 CN claimed
CN-101636187-A Biodegradable vascular support HEMOTEQ GMBH 2010-01-27 CN claimed
JP-2067218-A None JP disclosed
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS NATIVE CODE BIO LLC (US) 2026-04-02 US disclosed
EP-4665318-A2 THERAPEUTIC COMBINATIONS FOR INFLAMMATORY CONDITIONS AND DISORDERS Native Code Bio, LLC (US) 2025-12-24 EP disclosed
EP-4583856-A2 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS Native Code Bio, LLC (US) 2025-07-16 EP disclosed
EP-0027796-A4 CHROMAN AND CHROMANON-4 DERIVATIVES, PROCESS FOR THEIR PREPARATION, ANTIOXIDANT COMPOSITIONS CONTAINING SAME AND THEIR USE FOR STABILIZING EDIBLE FATS AND OILS. Z L LTD PARTNERSHIP (US) 1981-08-31 EP disclosed
EP-0027796-A1 CHROMAN AND CHROMANON-4 DERIVATIVES, PROCESS FOR THEIR PREPARATION, ANTIOXIDANT COMPOSITIONS CONTAINING SAME AND THEIR USE FOR STABILIZING EDIBLE FATS AND OILS. Z L LTD PARTNERSHIP (US) 1981-05-06 EP disclosed
US-4264509-A STORAGE STABILITY FOR FOODS CONTAINING OILS AND FATS Z-L LIMITED PARTNERSHIP (US) 1981-04-28 US disclosed
WO-1980002098-A1 ISOFLAVONES AND RELATED COMPOUNDS,METHODS OF PREPARING AND USING AND ANTIOXIDANT COMPOSITIONS CONTAINING SAME PARTNERSHIP LTD (US) 1980-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091047-A1 THERAPEUTIC COMBINATIONS FOR MOVEMENT DISORDERS HMBS, SNCA, PYGB RAB9A 459/4885KLK7 4682/4885HDAC6 4058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.